{"Clinical Trial ID": "NCT02186015", "Intervention": ["INTERVENTION 1:", "- Cholecalciferol", "Registered women received 50,000 IU cholecalciferol per week for 8 weeks.", "INTERVENTION 2:", "No cholecalciferol", "\u2022 Registered women with serum 25 (OH)D greater than or equal to 30 ng/ml have not received an intervention."], "Eligibility": ["Incorporation criteria:", "Metastatic breast cancer (Stage IV)", "A positive estrogen receptor disease confirmed histologically", "Women", "Serum 25(OH) < 30 ng/ml", "- 18 years", "Pre-menopausal or post-menopausal", "ECOG Performance status 0-2", "Adequate function of the organ as defined as GFR > 30 ml/min and serum calcium 10.4 mg/dl", "Any race/ethnicity", "- English", "No change in BCM treatment within 30 days of registration and/or considered clinically stable by their treating physician", "Willingness to sign written informed consent and complete questionnaires", "Ingestion of vitamin D supplementation is not related to the study", "- Exclusion criteria:", "Women with breast cancer in Stage I-III", "Serum levels of 25(OH)D 30 ng/ml", "- Unprocessed participation in the CNS", "History of kidney stones", "History of renal failure", "History of hyperparathyroidism", "History of hypersensitivity to vitamin D", "Not speaking English", "Currently pregnant or breastfeeding, or anticipating pregnancy", "Not wanting to stop ingesting calcium supplements (>1000 mg/d)", "* Not willing or unable to complete informed consent or study questionnaires.", "Psychiatry or other clinical conditions that prevent compliance with the study", "Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with study therapy or other activities"], "Results": ["Performance measures:", "Change in serum 25(OH)D", "A change in laboratory serum value from 25(OH)D to 8 weeks after supplementation was observed in participants who received a weekly supplementation of 50,000 IU of vitamin D3. The variation is expressed in laboratory serum value from 25(OH)D to 8 weeks less the initial value.", "Duration: 0, 8 weeks", "Results 1:", "Title of the arm/group: Cholecalciferol", "Description of the arm/group: Registered women received 50,000 IU cholecalciferol per week for 8 weeks.", "Total number of participants analysed: 10", "Median (interquartile range)", "Unit of measurement: ng/ml 32 (22-40)", "Results 2:", "Title of arm/group: No Cholecalciferol", "- Arm/group description: Registered women with serum 25 (OH)D greater than or equal to 30 ng/ml have not received an intervention.", "Total number of participants analysed: 0", "Median (interquartile range)", "Unit of measurement: ng/ml"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/11 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}